NCT02113657View on ClinicalTrials.gov

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 20, 2014

Primary Completion Date

November 4, 2019

Study Completion Date

November 4, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Ipilimumab

3 mg/kg by vein once every 3 weeks for a total of 4 doses.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Stand Up To Cancer

OTHER

collaborator

High Impact Clinical Research Support Program

OTHER

lead

M.D. Anderson Cancer Center

OTHER

NCT02113657 - T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter